Loading...
•
Jun 30, 2022
Boston Scientific Q2 2022 Earnings Report
Boston Scientific's financial performance exceeded expectations, driven by growth across all segments and regions.
Key Takeaways
Boston Scientific reported net sales of $3.244 billion for Q2 2022, representing a 5.4% increase on a reported basis and a 6.6% increase on an organic basis compared to the prior year period. The company's GAAP net income available to common stockholders was $246 million, or $0.17 per share, while adjusted EPS reached $0.44.
Net sales grew by 5.4% on a reported basis, 9.6% on an operational basis, and 6.6% on an organic basis compared to the prior year period.
GAAP net income available to common stockholders was $0.17 per share, and adjusted EPS was $0.44 per share.
Net sales growth was achieved in each reportable segment compared to the prior year period.
FDA 510(k) clearance received for the VersaCross Connect™ LAAC Access Solution.
Boston Scientific
Boston Scientific
Boston Scientific Revenue by Segment
Boston Scientific Revenue by Geographic Location
Revenue by Segment
MedSurg Revenue
CapyFin.comCardiovascular Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comEurope, Middle East & Africa Revenue
CapyFin.comAsia Pacific Revenue
CapyFin.com Forward Guidance
The company estimates net sales growth for the full year 2022 to be in a range of approximately 6.5 to 7.5 percent on a reported basis and estimates EPS on a GAAP basis in a range of $0.69 to $0.76 and adjusted EPS of $1.74 to $1.77. The company estimates net sales growth for the third quarter of 2022 to be in a range of approximately 6 to 8 percent on a reported basis and estimates EPS on a GAAP basis in a range of $0.20 to $0.24 and adjusted EPS of $0.43 to $0.45.
Positive Outlook
- Full year 2022 net sales growth is expected to be approximately 6.5 to 7.5 percent on a reported basis.
- Full year 2022 organic net sales growth is expected to be approximately 8 to 9 percent.
- Full year 2022 EPS on a GAAP basis is estimated to be in a range of $0.69 to $0.76.
- Full year 2022 adjusted EPS is estimated to be in a range of $1.74 to $1.77.
- Third quarter 2022 net sales growth is expected to be approximately 6 to 8 percent on a reported basis.
Challenges Ahead
- Foreign currency fluctuations are expected to negatively impact net sales growth.
- Acquisitions and divestitures may impact net sales growth.
- The ongoing COVID-19 pandemic could impact operations and financial results.
- U.S. and global economic conditions could impact performance.
- Manufacturing, distribution, and supply chain disruptions could affect results.
Revenue & Expenses
Visualization of income flow from segment revenue to net income